Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells
The proteasome inhibitor bortezomib (BTZ) has emerged as an effective drug for the treatment of multiple myeloma even though many patients relapse from BTZ therapy. The present study investigated the metabolic pathways underlying the acquisition of bortezomib resistance in multiple myeloma. We used...
Main Authors: | Daniele Tibullo, Cesarina Giallongo, Alessandra Romano, Nunzio Vicario, Alessandro Barbato, Fabrizio Puglisi, Rosalba Parenti, Angela Maria Amorini, Miriam Wissam Saab, Barbara Tavazzi, Renata Mangione, Maria Violetta Brundo, Giacomo Lazzarino, Giuseppe Alberto Palumbo, Giovanni Li Volti, Francesco Di Raimondo, Giuseppe Lazzarino |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/5/696 |
Similar Items
-
TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment
by: Grazia Scandura, et al.
Published: (2022-04-01) -
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01) -
Hyperglycosylation as an Indicator of Aging in the Bone Metabolome of <i>Oryzias latipes</i>
by: Remi O. Labeille, et al.
Published: (2024-09-01) -
O-GlcNAcylation: a pro-survival response to acute stress in the cardiovascular and central nervous systems
by: Qiu Xue, et al.
Published: (2024-03-01) -
Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor
by: Francesca Ricciardiello, et al.
Published: (2021-02-01)